ReviewRSC advances2025
Research progress on nanomaterial-empowered electrochemical biosensors for the detection of cardiac troponin I.
Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advancements in nanomaterials for the treatment and management of vascular surgeries: from drug delivery to biomedical implants.Frontiers in bioengineering and biotechnology · 2026Review
- Progress and Applications of Nanocomposites in the Technology of Biosensors.Nanomaterials (Basel, Switzerland) · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myocardial infarction (AMI) is a prevalent and high-risk type of cardiovascular disease (CVD) and a major threat to global human health. Rapid and accurate diagnosis of CVD is important to protect life and health. Cardiac troponin (cTnI) is considered the best biomarker for diagnosing AMI because of its high specificity and sensitivity to acute cardiomyocyte injury. In recent years, electrochemical sensing technology has provided a unique platform for accurate quantitative detection of cardiac biomarkers, effectively shifting early diagnosis of CVD to a higher level of precision and intelligence. Among them, electrochemical biosensors have demonstrated significant potential in monitoring the occurrence and development of CVD due to their benefits including rapid response, high sensitivity, and low cost. This work focuses on the use of various sensing materials including carbon-based materials, metal matrix composites, ceramic matrix composites, MOF composites and conductive polymer nanomaterials in detecting cTnI by electrochemical biosensors. We also discuss the application of various electrochemical biosensors in biomarker detection under different techniques. Moreover, this review systematically reveals its mechanism of action and unique benefits. It focuses on systematically presenting the latest research progress in the detection of cardiac biomarkers based on electrochemical platforms. We deeply analyze their current application status and future development trends, geared towards providing a comprehensive and future reference for research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.